SI
SI
discoversearch

 Biotech / Medical | IGEN International


Previous 10 | Next 10 
To: tuck who wrote (566)11/3/2000 10:53:07 AM
From: Biomaven
   of 1025
 
tuck,

It is a trickle play, but only to a limited extent. The big drivers of the stock in the near-term are going to be the Roche litigation, any deals with Bayer etc., and only secondarily the speed of uptake of the M-8 series. Further, the initial M-8 market is probably more pharma-oriented than biotech oriented.

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Biomaven who wrote (567)11/3/2000 11:18:14 AM
From: tuck
   of 1025
 
OT

HMMMMmm . . .

Time to start a "PharmaTrickle" thread? <g>

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read

To: John Zwiener who started this subject11/28/2000 4:40:10 PM
From: nigel bates
   of 1025
 
Nov. 28 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN - news) announced today that the U.S. District Court for the District of Maryland has appointed a Special Master to investigate the accuracy, completeness, and comprehensibility of Roche Diagnostics' financial and royalty data reported to IGEN and other issues central to IGEN's litigation with Roche. The appointment of the Special Master is a result of IGEN's motion to compel complete discovery from Roche, in which IGEN requested original source documents relevant to reporting, royalty, and other contract issues.
The Special Master is expected to begin fact-finding efforts shortly and is scheduled to complete a review and issue a final report by the end of February 2001, subject to extensions of up to a total of 60 days. According to the Court, the Special Master is to be provided with open access to Roche's files in Germany, the United States, the United Kingdom, Japan, Italy, and four other countries. Roche is under Court order to cooperate fully with the Special Master and his assistants and grant access to all requested documents and material, including electronic databases and programs.
``We are extremely pleased that the Court has now ordered the appointment of a Special Master, an impartial, neutral party to investigate and report on the accuracy and completeness of Roche's reporting to IGEN, among other matters,'' stated Samuel J. Wohlstadter, Chairman and Chief Executive Officer of IGEN. ``This will allow access to original Roche documents that had been denied to IGEN during the course of the litigation discovery to date. We believe that Roche has supplied materially misleading and inaccurate reports to IGEN in clear violation of its contractual obligations.''....

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: nigel bates who wrote (569)11/30/2000 2:39:24 AM
From: chalu2
   of 1025
 
Sounds like good news. Why is the stock price collapsing?

Share Recommend | Keep | Reply | Mark as Last Read

To: John Zwiener who started this subject11/30/2000 11:32:18 AM
From: nigel bates
   of 1025
 
Nov. 30 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN - news) reported today that it extended through January 31, 2001, the term of its joint venture agreement with Meso Scale Technologies, LLC (MST) to allow an independent committee of IGEN's outside directors to complete its review of issues concerning the joint venture and take any actions the committee may deem appropriate.
The joint venture was organized in 1995 for the development and commercialization of products utilizing a proprietary combination of multi-array technology owned or controlled by MST together with ORIGEN® and other technologies owned by IGEN. MST is an affiliated technology company neither owned nor controlled by IGEN. It holds certain rights to multiple patents and patent applications directed at multi-array technology.
Multi-array technology is expected to play an important role in meeting future needs for medical diagnostics, genomics, proteomics, food testing, and other biological detection applications. High-density multi-array devices are likely to be of comparable size and capacity to microelectronic devices and provide the sensitivity and discrimination required for the most sophisticated analytical instruments.
The independent committee has focused its efforts, in part, on evaluating the organization, operation, and potential continuation of the joint venture, which has been the subject of shareholder demands and threatened litigation. Special counsel is advising the independent committee....

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: nigel bates who wrote (571)11/30/2000 5:23:34 PM
From: Biomaven
   of 1025
 
subject of shareholder demands and threatened litigation

That quote to me is a signal they are going to do something drastic with what has now become a millstone. If they were going to carry on as before, my guess is that they would have made no mention of these complaints.

Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: Biomaven who wrote (572)12/4/2000 2:34:23 PM
From: tuck
   of 1025
 
Meanwhile, back at the royalty litigation ranch:

siliconinvestor.com

When this little rally fizzles, I am adding. If it doesn't fizzle, I'll be even happier.

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: tuck who wrote (573)12/5/2000 2:06:31 PM
From: tom pope
   of 1025
 
It's not fizzling, Tuck.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: tom pope who wrote (574)12/5/2000 2:13:51 PM
From: tuck
   of 1025
 
tom,

Can't complain. Besides, we'll see what the actual payroll and employment numbers are at the end of the week. I can see further warnings putting the brakes on, too, particularly in the PC sector. IGEN has a substantial short ratio, so this could be quite a move:

biz.yahoo.com 

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read


To: John Zwiener who started this subject12/6/2000 5:47:02 PM
From: sim1
   of 1025
 
IGEN Forms Strategic Alliance With nanoTools

IGEN to Market nanoTools' Reagents for Use With IGEN's Drug Discovery System

GAITHERSBURG, Md., Dec. 6 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN - news), announced today that it has formed a strategic alliance with nanoTools Antikorpertechnik GmbH & Co. KG, developer and marketer of monoclonal antibodies, to commercialize reagents for use with IGEN's M- SERIES(TM) biological detection system.

IGEN will market nanoTools' monoclonal antibodies -- both in their original form and tagged with IGEN's proprietary label -- for use as reagents with the M-SERIES system. These antibodies are expected to increase the number of M-SERIES users and enable them to conduct research in a wide range of life science fields, such as proteomics and drug discovery and development for Alzheimer's disease, cancer, and other diseases. An industry analyst estimates that pharmaceutical companies worldwide spent more than $1 billion on research reagents in 1999, with an annual growth rate of 15%.

IGEN markets the M-SERIES system, based on IGEN's proprietary ORIGEN® technology, to pharmaceutical and biotechnology companies, as well as government and academic life science researchers worldwide. M-SERIES instruments are distributed in Japan by SC BioSciences Corp., a subsidiary of Sumitomo Corp., with IGEN and its IGEN KK Japanese subsidiary responsible for the marketing and selling of all consumable reagents and assays for these instruments in the Japanese market.

``This strategic alliance with nanoTools further expands the range of high- quality reagents and assays we provide customers for use with our M-SERIES detection system,'' said Samuel J. Wohlstadter, IGEN's Chairman and Chief Executive Officer. ``This alliance also furthers our commitment to forging strategic alliances and partnerships with innovative companies such as nanoTools to develop and commercialize quality products that leverage our proprietary ORIGEN technology.''

``We are very pleased that IGEN has selected our antibodies for use with their drug discovery system,'' said Petra Schuessler, Ph.D., Chief Executive Officer of nanoTools. ``The synergy between nanoTools' products and IGEN's M- SERIES system will help expand markets for both companies.''

IGEN develops and markets detection systems based on its proprietary ORIGEN technology, which can assay a wide range of biological substances, including small molecules, proteins, nucleic acids, and microorganisms. This technology provides a unique combination of sensitivity, reliability, speed, and flexibility. ORIGEN-based systems are marketed by IGEN and its licensees and/or distributors -- Roche Diagnostics; Organon Teknika; Eisai Co., Ltd.; and Sumitomo Corp. More information about IGEN can be found at igen.com  .

Based in Teningen, Germany, nanoTools develops and markets monoclonal antibodies for signal transduction, cell biology, and Alzheimer's disease research, focusing particularly on antibodies specific to certain cleavage sites and phosphorylation sites. More information about nanoTools can be found at nanotools-antibodies.com  .

This release contains forward-looking statements about IGEN's plans to market nanoTools' antibodies, the expected impact on M-SERIES sales and applications, and plans for future strategic alliances. Actual results might differ materially from these statements due to risks and uncertainties, including those associated with success of the M-SERIES product enhancement and upgrade program, competitive products, market conditions, dependence on suppliers, and acceptance of new products. More complete descriptions of the risks applicable to IGEN appear in the company's documents filed with the Securities and Exchange Commission and available on request from the company. IGEN disclaims any intent or obligation to update these forward-looking statements.

IGEN and ORIGEN are registered trademarks, and M-SERIES is a trademark, of IGEN International, Inc.

SOURCE: IGEN International, Inc.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.